Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

There's Good News for 3 Biotech Names

And It comes after one of the best days of the year for the biotech sector.

The Wall of Worry Scales Higher and Higher

The debacle in Afghanistan and the potential for a return to COVID restrictions only add to the concerns for equities despite indices at all-time highs.

How Will a 'Broken Presidency' Affect the Economy and the Markets?

That's the question all investors should be asking themselves right now.

2 Drooping Pharma Stocks That Need to Put More Chips on the Table

Supernus Pharmaceuticals and Exelixis Inc. have the cash to be able to take some chances in order to improve their business prospects.

Confidence of Consumers Sags as They Feel the Sting of Inflation

From rent to food and gasoline, the prices people are paying are climbing and that is putting a pessimistic hue on their view of the world.

Here's What to Do When You Don't Have Strong Conviction in the Markets

Sometimes it's best to move to the sidelines until something changes.

Inflation, Infrastructure Spending, and Stagflation

Regardless of one's politics, this ought to scare you as an investor.

2 Biotech Stocks to Watch

Dynavax Technologies and Albireo Pharma are names for consideration while investors wait for sentiment on the biotech sector to eventually turn around.

Is This the Start of a Long-Awaited Rebound for Biotech?

Life has not been easy for the small-cap biotech investor so far in 2021.

Solid Results From These 2 Small-Cap Stocks Should Propel Them Higher

Shares of Extreme Networks and Beazer Homes look promising based on the companies' recent quarterly reports.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight